Aurora Cannabis expands medical high‑THC flower and resin cartridges in Australia and New Zealand
- Aurora expands medical products in Australia and New Zealand, adding high‑THC flowers (NZ) and resin cartridges (Australia).
- Products specify THC/CBD metrics (flowers 9–29% THC; Half Moon 9% THC/13% CBD; cartridges 780 mg/g THC).
- Aurora to ring Nasdaq closing bell Feb. 18, signaling its global, medical‑first strategy and international expansion.
Aurora widens medical range in Australia and New Zealand
Aurora Cannabis is expanding its medical product lineup in Australia and New Zealand, underscoring a strategic push to deepen its presence in key international markets. The company introduces high‑THC flower products in New Zealand and new resin cartridges in Australia, emphasising measured cannabinoid profiles, regulatory compliance and prescriber support as central to the launch.
Targeted clinical formats for prescribers and patients
Aurora launches two high‑THC flower strains in New Zealand this month — Big Wave (hybrid, THC 26%, CBD <1%) and Night Ride (indica, THC 29%, CBD <1%) — with a balanced Half Moon (hybrid, THC 9%, CBD 13%) arriving in the first quarter of fiscal 2027. In Australia, four resin cartridges debut this month: Chemango Kush, Cosmic Cream and Lunar Express (all indica) and Soul Train Haze (sativa). Aurora specifies the cartridges at 780 mg THC per gram and CBD levels below 10 mg/g, providing quantified metrics intended to aid dose selection and clinical decision‑making.
The company highlights that the products derive from proprietary genetics and are manufactured at EU‑GMP and TGA‑GMP certified facilities in Canada, a point it says ensures consistent quality, safety and reliable supply for medical patients. Stanley Sack, interim managing director of MedReleaf Australia, says Australia remains one of Aurora’s largest international medical cannabis markets and that the firm will continue investing in the region. Aurora frames the launches as part of a broader “medical‑first” strategy to offer diversified formats that support prescribers and improve patient access across regulated systems.
Compliance, supply and clinical consistency
By publishing explicit THC and CBD specifications — flower THC from 9% to 29% and CBD up to 13% in Half Moon — Aurora aims to provide clinicians with predictable cannabinoid profiles to support therapeutic outcomes and regulatory compliance. The company underscores its global footprint across a dozen markets, high‑quality medical portfolio and GMP‑certified manufacturing as foundations for scaling supply chains and sustaining market access.
Nasdaq bell ceremony signals global focus
Aurora plans a Nasdaq closing bell ceremony in New York on Feb. 18, led by CEO Miguel Martin and senior leaders, presenting the event as a public signal of its evolution into a globally focused, medical‑first cannabis company and a celebration of its international expansion.
R&D and patient‑first messaging
The company reiterates that its medical business drives growth and cites continued investment in R&D, regulatory expertise and a patient‑focused supply chain as priorities for capturing high‑margin, clinically oriented markets in Canada, Europe, Australia and New Zealand.
